Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain

European Journal of Neuroscience

Volumn 19, Issue 10, 2004, Pages 2711-2719

  Swatton, Jane E ^a   Sellers, Lynda A ^a   Faull, Richard L M ^b   Holland, Anthony ^c   Iritani, Shuji ^d   Bahn, Sabine ^a,c  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

Author keywords

cdk5; GSK 3 ; Neurodegeneration; Tau

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN; CELL SURVIVAL; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCHIZOPHRENIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOTTING, WESTERN; BRAIN; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; DOWN SYNDROME; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE TISSUE PROTEINS; PHOSPHORYLATION; POSTMORTEM CHANGES; SCHIZOPHRENIA;

EID: 2942589223     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-816X.2004.03365.x     Document Type: Article

References (41)

1. Anderton, B.H., Betts, J., Blackstock, W.P., Brion, J.P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J.M., Gibb, G., Hanger, D.P., Hutton, M., Kardalinou, E., Leroy, K., Lovestone, S., Mack, T., Reynolds, C.H. & Van Slegtenhorst, M. (2001) Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp., 73-80.
2. Atzori, C., Ghetti, B., Piva, R., Srinivasan, A.N., Zolo, P., Delisle, M.B., Mirra, S.S. & Migheli, A. (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol., 60, 1190-1197.
3. Braak, H. & Braak, E. (1998) Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm. Suppl., 53, 127-140.
4. Casanova, M.F., Stevens, J.R., Brown, R., Royston, C. & Bruton, C. (2002) Disentangling the pathology of schizophrenia and paraphrenia. Acta Neuropathol. (Berl.), 103, 313-320.
5. Chang, L. & Karin, M. (2001) Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
6. DeKosky, S.T., Scheff, S.W. & Styren, S.D. (1996) Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration, 5, 417-421.
7. Dickson, T.C. & Vickers, J.C. (2001) The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience, 105, 99-107.
8. Dineley, K.T., Westerman, M., Bui, D., Bell, K., Ashe, K.H. & Sweatt, J.D. (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci., 21, 4125-4133.
9. Doble, B.W. & Woodgett, J.R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 116, 1175-1186.
10. Eldar-Finkelman, H. (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med., 8, 126-132.
11. Ferrer, I., Barrachina, M. & Puig, B. (2002) Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. (Berl.), 104, 583-591.
12. Ferrer, I., Blanco, R., Carmona, M., Ribera, R., Goutan, E., Puig, B., Rey, M.J., Cardozo, A., Vinals, F. & Ribalta, T. (2001) Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol., 11, 144-158.
13. Ghribi, O., Herman, M.M. & Savory, J. (2003) Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J. Neurosci. Res., 71, 853-862.
14. Goedert, M., Hasegawa, M., Jakes, R., Lawler, S., Cuenda, A. & Cohen, P. (1997) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett., 409, 57-62.
15. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., Parisi, J.E. & Hyman, B.T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 41, 17-24.
16. Gotz, J., Chen, F., van Dorpe, J. & Nitsch, R.M. (2001) Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science, 293, 1491-1495.
17. Hanger, D.P., Betts, J.C., Loviny, T.L., Blackstock, W.P. & Anderton, B.H. (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem., 71, 2465-2476.
18. Harwood, A.J. (2000) Signal transduction: Life, the universe and. . .development. Curr. Biol., 10, R116-R119.
19. Iqbal, K. & Grundke-Iqbal, I. (1996) Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Ann. NY Acad. Sci., 777, 132-138.
20. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T. & Imahori, K. (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett., 325, 167-172.
21. Lee, M.S., Kwon, Y.T., Li, M., Peng, J., Friedlander, R.M. & Tsal, L.H. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature, 405, 360-364.
22. Leroy, K., Boutajangout, A., Authelet, M., Woodgett, J.R., Anderton, B.H. & Brion, J.P. (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol. (Berl.), 103, 91-99.
23. Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, S.H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M. & McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 293, 1487-1491.
24. Liu, F., Iqbal, K., Grundke-Iqbal, I. & Gong, C.X. (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett., 530, 209-214.
25. Lovestone, S. & Reynolds, C.H. (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience. 78, 309-324.
26. Marks, N. & Berg, M.J. (2003) APP processing enzymes (secretases) as therapeutic targets: insights from the use of transgenics (Tgs) and transfected cells. Neurochem. Res., 28, 1049-1062.
27. Martinez, A., Alonso, M., Castro, A., Perez, C. & Moreno, F.J. (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 45, 1292-1299.
28. Morishima, Y., Gotoh, Y., Zieg, J., Barrett, T., Takano, H., Flavell, R., Davis, R.J., Shirasaki, Y. & Greenberg, M.E. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci., 21, 7551-7560.
29. Mukaetova-Ladinska, E.B., Hurt, J., Honer, W.G., Harrington, C.R. & Wischik, C.M. (2002) Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neurosci. Lett., 317, 161-165.
30. Nagy, Z., Esiri, M.M., Jobst, K.A., Morris, J.H., King, E.M., McDonald, B., Litchfield, S., Smith, A., Barnetson, L. & Smith, A.D. (1995) Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia, 6, 21-31.
31. Pantelis, C., Velakoulis, D., McGorry, P.D., Wood, S.J., Suckling, J., Phillips, L.J., Yung, A.R., Bullmore, E.T., Brewer, W., Soulsby, B., Desmond, P. & McGuire, P.K. (2003) Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361, 281-288.
32. Pei, J.J., Braak, H., An, W.L., Winblad, B., Cowbum, R.F., Iqbal, K. & Grundke-Iqbal, I. (2002) Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res. Mol. Brain Res., 109, 45-55.
33. Phiel, C.J., Wilson, C.A., Lee, V.M. & Klein, P.S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 423, 435-439.
34. Reynolds, C.H., Betts, J.C., Blackstock, W.P., Nebreda, A.R. & Anderton, B.H. (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J. Neurochem., 74, 1587-1595.
35. Savage, M.J., Lin, Y.G., Ciallella, J.R., Flood, D.G. & Scott, R.W. (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci., 22, 3376-3385.
36. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Mutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D. & Younkin, S. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med., 2, 864-870.
37. Shoji, M., Iwakami, N., Takeuchi, S., Waragai, M., Suzuki, M., Kanazawa, I., Lippa, C.F., Ono, S. & Okazawa, H. (2000) JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res. Mol. Brain Res., 85, 221-233.
38. Sperber, B.R., Leight, S., Goedert, M. & Lee, V.M. (1995) Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci. Lett., 197, 149-153.
39. Tokuda, T., Fukushima, T., Ikeda, S., Sekijima, Y., Shoji, S., Yanagisawa, N. & Tamaoka, A. (1997) Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42 (43) are elevated in Down's syndrome. Ann. Neurol., 41, 271-273.
40. Wisniewski, K.E., Dalton, A.J., McLachlan, C., Wen, G.Y. & Wisniewski, H.M. (1985) Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology, 35, 957-961.
41. Zhu, X., Rottkamp, C.A., Hartzler, A., Sun, Z., Takeda, A., Boux, H., Shimohama, S., Perry, G. & Smith, M.A. (2001) Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem., 79, 311-318.